“Novo is more dependent on Tresiba than ever”
Major US bank Morgan Stanley says in a new analysis that Novo Nordisk has never been more dependent on the diabetes drug Tresiba than the company is at the moment. The bank lowers its target price for the Novo share.
BY BENJAMIN WERNER CHRISTENSEN
Tresiba is by far the most important product for Novo Nordisk at the moment, analysts from Morgan Stanley conclude in a new report, pointing out that they are not the only ones to think so.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
